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Background: BRCA1 mutation carriers have an 85% risk of developing breast cancer but the risk of developing
non-hereditary breast cancer is difficult to assess. Our objective is to test whether a DNA methylation (DNAme)
signature derived from BRCA1 mutation carriers is able to predict non-hereditary breast cancer.
Methods: In a case/control setting (72 BRCA1 mutation carriers and 72 BRCA1/2 wild type controls) blood cell DNA
samples were profiled on the Illumina 27 k methylation array. Using the Elastic Net classification algorithm, a
BRCA1-mutation DNAme signature was derived and tested in two cohorts: (1) The NSHD (19 breast cancers developed
within 12 years after sample donation and 77 controls) and (2) the UKCTOCS trial (119 oestrogen receptor positive
breast cancers developed within 5 years after sample donation and 122 controls).
Results: We found that our blood-based BRCA1-mutation DNAme signature applied to blood cell DNA from women in
the NSHD resulted in a receiver operating characteristics (ROC) area under the curve (AUC) of 0.65 (95% CI 0.51 to 0.78,
P = 0.02) which did not validate in buccal cells from the same individuals. Applying the signature in blood DNA from
UKCTOCS volunteers resulted in AUC of 0.57 (95% CI 0.50 to 0.64; P = 0.03) and is independent of family history or any
other known risk factors. Importantly the BRCA1-mutation DNAme signature was able to predict breast cancer mortality
(AUC = 0.67; 95% CI 0.51 to 0.83; P = 0.02). We also found that the 1,074 CpGs which are hypermethylated in BRCA1
mutation carriers are significantly enriched for stem cell polycomb group target genes (P <10−20).
Conclusions: A DNAme signature derived from BRCA1 carriers is able to predict breast cancer risk and death years in
advance of diagnosis. Future studies may need to focus on DNAme profiles in epithelial cells in order to reach the AUC
thresholds required of preventative measures or early detection strategies.Background
Breast cancer is the most common cancer in women, af-
fecting at least 1 in 10 women in the western world. The
potential to predict breast cancer and offer preventive
measures is an effective intervention in women with an
inherited predisposition to breast cancer due to mutations
in BRCA1/2 genes [1]. However, these account for less than
10% of breast cancers [2]. While extensive genome-wide* Correspondence: m.widschwendter@ucl.ac.uk
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unless otherwise stated.association studies have identified a number of single
nucleotide polymorphisms (SNPs) associated with breast
cancer risk [3], epidemiological models that include risk
associated SNPs yield a receiver-operating-characteristic
(ROC) area under the curve (AUC) of only 62%, a modest
4% improvement over the AUC of epidemiological models
[4].
Predicting the likelihood of breast cancer development
is therefore still challenging not only because the sensi-
tivity of current strategies is low [4] but also because
11% to 52% of screen-detected breast cancers may be
an over diagnosis of cancers which would have never
become clinically evident [5-7]. Hence a biomarker thatLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Anjum et al. Genome Medicine 2014, 6:47 Page 2 of 11
http://genomemedicine.com/content/6/6/47could predict the risk of developing breast cancer particu-
larly in those with a poor prognosis and which is also in-
dependent of familial predisposition is urgently needed.
It is known that epigenetic variation contributes to
inter-individual variation in gene expression and thus may
contribute to variation in cancer susceptibility [8-10].
DNAme is the most studied mechanism of epigenetic
gene regulation and represents a biologically and chem-
ically stable signal. Aberrant DNA methylation is also a
hallmark of cancer [9,11], in particular increased promoter
DNAme at stem cell differentiation genes (Polycomb-
Repressive Complex 2 (PRC2) Group Target genes (PCGTs))
[12-19]. Initial evidence suggests that BRCA1 is a key
negative modulator of PRC2 and that loss of BRCA1 in-
hibits stem cell differentiation and enhances an aggressive
breast cancer phenotype by affecting PRC2 function [20].
Several proof of principle studies using a target gene ap-
proach or assessment of global DNA methylation analys-
ing samples collected at the time of diagnosis provided
the first evidence for the feasibility of breast cancer risk
prediction using DNA methylation based markers [21-32].
It was also recently demonstrated that DNAme profiles in
blood are able to predict cancer risk (on average 1.3 years
in advance) within a group of women whose sisters had
developed breast cancer [33].
Here we tested the hypothesis that women with an ex-
tremely high breast cancer risk (due to a BRCA1 muta-
tion) carry a specific methylation signature in peripheral
blood cells, which is also able to predict sporadic breast
cancer incidence and death. We also tested whether this
signature is tissue-specific.
Methods
Data from three different studies were used.
BRCA1 study
We analysed whole blood samples from two cohorts of
BRCA1 mutation carriers and controls without a BRCA1
mutation (see Figure 1 and Additional file 1).
MRC National Survey of Health and Development (NSHD)
We analysed both blood cells and buccal cells from a
sample of women from the NSHD, a birth cohort study
of men and women born in Britain in March 1946
[34-36]. A total of 152 (75 cancer cases and 77 controls)
women were selected from those who provided both a
peripheral blood and a buccal cell sample at the age of
53 years in 1999, who had not previously developed any
cancer and who had complete information on epidemio-
logical variables of interest and follow-up. We analysed
>480,000 CpGs (using the Illumina 450 k array) in the
46 women who developed an invasive non-skin cancer
(19 breast cancer, 5 reproductive tract and 22 other can-
cers; diagnosed 1 to 7 years after 53 years and an averageof 4.75 years) and in the women (n = 77) who did not
develop any cancer during the 12-year follow-up (for
descriptive analysis see Additional file 2).
United Kingdom Collaborative Trial of Ovarian Cancer
Screening (UKCTOCS)
We analysed serum DNA samples (which largely represent
white blood cell DNA in this cohort - see Additional files 3
and 4) from postmenopausal women who developed
breast cancer (n = 119) or remained cancer-free during
the follow-up period (n = 122, maximum of 12 year
follow-up (2001 to 2013)).
Ethics
All studies were approved by the relevant research ethics
committee or institutional review board. Informed con-
sent was obtained by all volunteers and conforms with
the Declaration of Helsinki. The BRCA1 study was ap-
proved by the ethics committee of the General University
Hospital, Prague (No. 1199/07 S-IV). The NSHD epigen-
etics study was approved by the Central Manchester Re-
search Ethics Committee (REC reference: 07/H1008/168).
UKCTOCS was approved by the UK North West Multi-
centre Research Ethics Committees (North West MREC
00/8/34). Ethical approval for this nested case control
study was obtained from the Joint UCL/UCLH Commit-
tees on the Ethics of Human Research (REC reference:
06/Q0505/102).
DNA methylation analysis
The DNA from whole blood and tissues was extracted at
UCL [36] and at Gen-Probe [37]. Methylation analysis was
performed using the validated Illumina Infinium Human
Methylation27 BeadChip [16] or the Illumina Infinium
Human Methylation450 BeadChip for NSHD samples.
The methylation status of a specific CpG site was calculated
from the intensity of the methylated (M) and unmethylated
(U) alleles, as the ratio of fluorescent signals β =Max(M,0)/
(Max(M,0) +Max(U,0) + 100). On this scale, 0 < β < 1,
with β values close to 1 (0) indicating 100% methylation
(no methylation) (see Additional file 4).
Data availability
Data from two of the studies in this manuscript have
been deposited in the Gene Expression Omnibus repository
under the accession numbers (GSE58119), (GSE57285),
(GSE32396). The NSHD data are made available to
researchers who submit data requests to mrclha.swiftin-
fo@ucl.ac.uk; see full policy documents at [38]. Managed
access is in place for this 68-year-old study to ensure that
use of the data is within the bounds of consent given pre-
viously by participants, and to safeguard any potential
threat to anonymity since the participants are all born in
the same week.
NSHD 
BRCA1 Study
2514 CpG probes (fdr 0.3) differentially methylated between 
BRCA1 mutants and BRCA1 wild types
Multivariate Regression
Adjusted for cancer presence, age and cohort
Cohort 1- WBC
with cancer (n=15)
no cancer (n=15)
30 BRCA1 mutant 
30 BRCA1 wild type 
Cohort 2- WBC
42 BRCA1 wild type
42 BRCA1 mutant 
with cancer (n=15)
no cancer (n=15)
with cancer (n=35)
no cancer (n=7)
with cancer (n=0)
no cancer (n=42)
Ensemble Signature Identification
Using Elastic Net
100 training and test set partitions of 72 BRCA1 mutants and
72 BRCA1 wild types
Identified a single signature comprising of 1829 CpGs 
Stacked Generalization
UKCTOCS
2 samples collected, on average 2
years, prior to cancer diagnosis
Serum DNA
Inv. ER+ BC2 (n=119)
Healthy controls (n=122)
Tested in 
WBC Buccal 
Inv. BC1 (n=19)
Inv. other cancers1 (n=27)
Healthy controls (n=77)
1 samples collected, on average 4.75 years, prior to 
cancer diagnosis
D
is
c
o
v
e
ry
 o
f D
N
A 
m
e
th
yla
tio
n
 s
ig
na
tu
re
 in
 
W
BC
 o
f h
ig
h-
ris
k 
w
om
e
n
Va
lid
at
io
n
 in
 
ge
ne
ra
l p
op
ul
a
tio
n
 s
a
m
pl
e
s 
pr
ed
at
in
g 
di
a
gn
os
is
Inv. BC1 (n=19)
Inv. other cancers1 (n=27)
Healthy controls (n=77)
Figure 1 Study design and identification/validation of the BRCA1-mutation DNAme risk signature. AUC, receiver operating characteristics
area under the curve; BC, breast cancer; FDR, false discovery rate; inv., invasive; WBC, white blood cells.
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Differential methylation analysis
From the BRCA1 study, differentially methylated CpGs,
with false discovery rate (FDR) corrected P values, be-
tween BRCA1 mutant carriers and BRCA1 wild type
samples were identified via a multivariate logistic regres-
sion that was adjusted for age, batch and the presence
of cancer.Ensemble signature identification
The elastic net classification method was chosen for our
study as it has been shown to be particularly effective
when the number of predictors is far greater than the
number of training points [39]. The elastic net method,
as implemented in the glmnet R-package [40], identified
a classifier comprising 1,829 CpGs with non-zero regres-
sion coefficients (see Additional file 4).
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To evaluate its predictive accuracy, the identified classifier
was tested on two independent datasets: (1) NSHD, and
(2) UKCTOCS. For each individual, risk scores, based on
their methylation profiles, were estimated and correlated
to their disease status. An AUC value was then obtained
via Somers’ Dxy rank correlation [41] (see Additional file 4).
Results
DNA methylation signature in white blood cells (WBC)
associated with BRCA1 mutation status
We analysed DNAme of 27,578 CpGs in WBC samples
from a total of 72 women with a known BRCA1 mutation
and 72 women with no mutation in the BRCA1 or BRCA2
gene (Figure 1 and Additional file 1). The presence of a
cancer has been shown to modulate the composition of
WBCs and DNAme profiles in peripheral blood [42] and
hence we used a mixture of women who did and who did
not develop breast cancer in order to be able to adjust for
this. Using a multivariate regression model that included
age, cohort and cancer status as covariates we were able
to rank CpGs according to the significance of the associ-
ation between their DNAme profile and mutation status.
On applying a relaxed threshold of FDR <0.3 we observed
a total of 2,514 BRCA1-mutation associated CpGs, of
which 1,422 (57%) were hypermethylated (hyperM) and
1,092 (43%) were hypomethylated (hypoM) in women
who had a BRCA1 mutation (Figure 1, Additional file 5),
representing a highly significant skew towards hyper-
methylated CpGs (Binomial test P < 1e-10). To arrive at
a specific DNAme signature, which would allow classifi-
cation of independent samples, we used the elastic net
(ELNET) framework (see Additional file 4), which re-
sulted in a signature consisting of 1,829 CpGs (Figure 2,
Additional file 6).
Given that PCGT methylation is a hallmark of almost
all cancers and that a BRCA1 defect in normal non-
neoplastic cells is likely to silence PCGTs and comprom-
ise cell differentiation [20], we posited that our BRCA1
DNAme signature may be able to predict sporadic breast
cancer. Interestingly, Gene Set Enrichment Analysis (GSEA)
[43,44] on the 1,074 hypermethylated (Additional file 7) and
755 hypomethylated (Additional file 8) CpGs of the BRCA1-
mutation signature demonstrated the association of BRCA1
mutation with promoter hypermethylation of PCGTs. In-
deed, the top categories of genes, associated with the
hypermethylated CpGs in BRCA1 mutation carriers, were
significantly (P <10−10) enriched for stem cell PCGTs irre-
spective of the definition used (Figure 2, Additional file 7).
In contrast, none of the gene categories associated with
those CpGs which are hypomethylated in BRCA1 muta-
tion carriers reached significance based on adjusted P
values (Additional file 8). Even the GSEA on the 105
CpGs with a more stringent FDR (<=0.05) associatedwith BRCA1 mutation in white blood cells demonstrated
the enrichment of PCGTs (P < =0.02) (Additional file 9).
BRCA1-mutation DNAme signature and breast cancer risk
in peripheral blood cells in the NSHD
In order to test whether the BRCA1-mutation DNAme
signature is able to identify women who will develop
breast cancer we analysed one of the best available char-
acterised longitudinal cohorts (Additional file 2). Apply-
ing the BRCA1-mutation DNAme signature (out of the
1,829 BRCA1 CpGs, 1,722 were present on the 450 k
Illumina methylation array), yielded a breast cancer risk
AUC = 0.65 (0.51 to 0.78, P = 0.02) (Figure 3A). Interest-
ingly, the BRCA1 signature also significantly predicted
the future development of invasive non-breast cancers
(AUC = 0.62; 0.50 to 0.74; P = 0.04) (Additional file 10A).
Consistent with the view that DNAme is tissue-specific,
our DNAme signature - derived from peripheral blood
cells from women with known BRCA1 status - was not
able to predict invasive breast cancer (Figure 3B) or
invasive non-breast cancer (Additional file 10B) in the
buccal cell DNAme profiles obtained at the same time
from the same women who provided blood DNA.
BRCA1-mutation DNA methylation signature and breast
cancer risk in serum DNA in the UKCTOCS cohort
Less than 10% of invasive breast cancers are due to a
BRCA1 mutation [45] and therefore it is unlikely that
the predictive capacity of the BRCA1-mutation DNAme
signature in the NSHD cohort was due to the correct
identification of BRCA1 mutation carriers. Nevertheless
in order to further substantiate that the BRCA1-muta-
tion DNAme signature identifies sporadic cancers, we
performed a nested case–control study within the UKC-
TOCS cohort (a 202,638 postmenopausal women cohort,
who based on their family history were not at an increased
risk of ovarian or breast cancer - see Additional files 3 and
4). As BRCA1-associated cancers are far more likely (75%)
to be oestrogen receptor (ER) negative [46], we solely
focused our analysis on women who provided a blood
sample between 0.42 and 4.18 years (average 2 years)
before they developed an ER positive invasive breast
cancer (n = 119) and matched (on age at blood donation
and recruitment centre) them to 122 women who did
not develop a breast cancer during the follow-up period
(5.61 to 12 years, average follow-up 11.92 years). As
there was no whole blood DNA samples available from
the women in UKCTOCS, we used serum-free DNA as
a source of material for this analysis. Since >95% of
blood samples were only spun down 24 to 48 h after the
blood draw, it was important for us to identify the likely
source of DNA in the serum samples. Although we were
not able to definitely identify the source, the evidence
clearly pointed towards an enriched for WBC DNA (see
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Figure 2 CpGs (n = 1829), which are differentially methylated in WBCs between BRCA1 mutation carriers and wild type controls and
which comprise the ‘BRCA1-mutation DNA methylation signature’. Heatmap of normalised methylation values (blue = relative high
methylation, yellow = relative low methylation) of CpGs comprising the BRCA1-mutation DNAme signature. The first colour bar at the top denotes
the two main clusters where ‘red’ reflects the samples with a BRCA1 mutation whereas ‘green’ reflects samples without a mutation in BRCA1 or
BRCA2 gene. The distribution of cancer cases is given in the second colour bar indicating women who had developed a breast cancer in purple.
Right panel shows the enrichment of the top components of the gene set enrichment analysis in the hyper- and hypomethylated subset of CpGs;
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signature predicted the development of an ER positive
breast cancer with an AUC = 0.57 (0.50 to 0.64; P = 0.03)
(Figure 3C) independent of whether the sample was
taken less or more than 2 years prior to diagnosis (see
Additional file 12). Importantly, the BRCA1-mutation
DNAme signature also substantially overlapped with
an ER + breast cancer specific risk signature (Additional
file 13), which we derived de novo in the UKCTOCS
cohort (P <2 x 10−33, Figure 3D). Of note, in the breast
cancer specific risk signature, we also observed enrich-
ment of biological terms, all crucially involved in stem
cell differentiation and biology (Additional file 14).Again, these stem cell gene categories were only enriched
among CpGs hypermethylated in cases, but not among
CpGs hypomethylated in cases (Additional file 15). This
observation is particularly pertinent given that NIPP1,
PRC2, MSX1 and NANOG all suppress differentiation
through occupation and suppression of specific gene
sets.
BRCA1-mutation DNAme signature identifies women
years in advance of fatal breast cancer diagnosis
In order to test whether the BRCA1-mutation DNAme
signature is able to predict not only incidence but also
breast cancer mortality we performed ROC statistics in
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Table 1 Characteristics of the samples used from the
UK Collaborative Trial of Ovarian Cancer Screening
(UKCTOCS)
Factors Methylation signature P value
Positive Negative
OCP use in the past Yes 72 60 0.604
No 55 54
Pregnancies <6 months Yes 32 35 0.387
No 95 78
Pregnancies >6 months Yes 109 102 0.439
No 18 12
Mother breast cancer Yes 14 11 0.833
No 113 103
Grandmother(s)
breast cancer
Yes 2 7 0.0887
No 125 107
Sister(s) breast cancer Yes 5 11 0.118
No 122 103
Aunt(s) breast cancer Yes 12 6 0.233
No 115 108
Any family member
breast cancer
Yes 29 32 0.376
No 98 82
Alcohol units per week Yes 78 68 1
No 26 23
Smoker Yes 41 37 0.89
No 84 72
The samples were categorised according to their individual risk scores. These risk
scores are the product of the methylation profile with the regression coefficients
of the signature. The statistical significance was assessed by a two-sided, Fisher’s
exact test. The missing values were excluded from the analysis.
(See figure on previous page.)
Figure 3 Validation of the BRCA1-mutation DNAme signature in two independent prospective cohorts. ROC curves and AUC statistics to
predict future breast cancer (BC) incidence applying the BRCA1-mutation DNAme signature in white blood cells (WBCs) (A) and in buccal (BUCC)
cells (B) of the NSHD cohort and in serum DNA of the UKCTOCS cohort (C). Overlap of the top CpGs differently methylated in WBC between
BRCA1 mutant and wild type (BRCA1 study) and the top CpGs differently methylated in serum DNA between women who have developed
oestrogen receptor positive BCs and women who remained cancer-free (D). ROC curve and AUC statistics to predict deadly BCs applying the
BRCA1-mutation DNAme signature in serum DNA in the UKCTOCS cohort (E) and Kaplan Meier curve (and hazard ratio (HR)) of future breast
cancer patients with a high and low BRCA1-mutation DNAme score in serum DNA (F).
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breast cancer (n = 10) during the follow-up period with
women who did not develop breast cancer (Figure 3E)
and found an AUC = 0.67 (0.51 to 0.83; P = 0.02). In line
with these findings women with a higher than average
BRCA1-mutation DNAme signature score were 8.46 (95%
CI 1.06 to 67.69) -fold more likely to die from breast can-
cer (P = 0.04) than those with lower than average scores
(Figure 3F). Interestingly, apart from the number of nodes,
none of the other clinico-pathological features or treat-
ment modalities was associated with the BRCA1-mutation
DNAme signature in these ER positive breast cancers
(Additional file 16).
BRCA1-mutation DNAme signature and association with
epidemiological and hormonal risk markers
Next, we were interested whether our DNAme signature
could be explained by any of the breast cancer risk fac-
tors we had available for the UKCTOCS cohort. Inter-
estingly, neither any of the epidemiological breast cancer
risk factors nor any of the hormones (Tables 1, 2 and 3)
we have analysed in the same serum samples was associ-
ated with our BRCA1-mutation DNAme signature. Inter-
estingly, when we analysed women with and without a
family history [47] separately, both BC incidence and
death was predicted by our BRCA1-DNAme signature
only in the group without family history (Additional file
17), but not in the (obviously very small) group of women
with any family history (Additional file 18).
Discussion
Here we have provided several novel lines of evidence
indicating that DNAme profiles obtained in cells from
women with a BRCA1 mutation have the potential to
indicate future breast cancer development (and death)
many years in advance of diagnosis. Our findings also
show that genes encoding developmental transcription
factors integral for stem cell differentiation and biology
are hypermethylated in women predisposed to breast
cancer.
Our data suggest that the BRCA1-associated DNAme
signature is a risk predicting signature rather than an
early detection signature, because: (1) the DNAme sig-
nature was derived from WBCs in women with a known
BRCA1 status and was adjusted for cancer status (analysisincluded BRCA1 carriers without cancer at the time of
sample draw); (2) the time from sample draw to diagnosis
had no dramatic impact on the strength of association
between DNAme and potential for breast cancer develop-
ment; (3) the signature was validated in two independent
cohorts; (4) we observed a very strong overlap of CpGs as-
sociated with BRCA1 mutation (BRCA1 study) and CpGs
indicating future breast cancer risk (UKCTOCS); and
finally (5) the signature was also associated with invasive
non-breast cancers.
Table 2 Additional characteristics of the samples used
from the UK Collaborative Trial of Ovarian Cancer
Screening (UKCTOCS)
Breast cancer
(#Samples)
Methylation signature P value
Positive (SD) Negative (SD)
Mean BMI
(kg/m2)
Yes (119) 27.39 (5.3) 27.27 (5.0) 0.9
No (121) 26.63 (5.17) 26.57 (4.64) 0.95
Mean age at
menarche (years)
Yes (117) 12.89 (1.48) 12.65 (1.61) 0.4
No (122) 12.97 (1.76) 13.24 (1.77) 0.39
Mean age at
menopause
(years)
Yes (119) 49.58 (5.78) 48.37 (7.65) 0.34
No (122) 47.57 (7.99) 48.74 (5.79) 0.36
The samples were categorised according to their individual risk scores. These
risk scores are the product of the methylation profile with the regression
coefficients of the signature. The statistical significance was assessed by a
t-test. The missing values were excluded from the analysis.
Table 3 Characteristics of the samples used from the UK Colla
Hormones Breast cancer (#Samples)
Mean oestradiol, pg/mL Yes (65)
No (115)
Mean free oestradiol, pmol/L Yes (65)
No (114)
Mean oestrone, pg/mL Yes (67)
No (117)
Mean androstendione, nmol/L Yes (64)
No (118)
Mean testosterone, nmol/L Yes (65)
No (115)
Mean free testosterone, ng/dl Yes (65)
No (115)
Mean SHBG, nmol/L Yes (66)
No (116)
Mean progesterone, ng/mL Yes (66)
No (114)
Mean DHEAS, ug/dl Yes (66)
No (116)
Mean ER alpha, pg/mL Yes (67)
No (120)
Mean ER beta, pg/mL Yes (67)
No (120)
Mean AR, ng/mL Yes (67)
No (119)
The samples were categorised according to their individual risk scores. These risk sc
of the signature. The statistical significance was assessed by a t-test. The missing va
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BRCA1-mutation associated CpGs are highly enriched
for PCGTs which we and others have previously shown
to be an epigenetic hallmark of cancer tissue [12-18] and
which are among the earliest, if not the earliest, molecular
changes in human carcinogenesis [18] was an exciting
finding because it fully supports recent data demonstrat-
ing that a BRCA1 defect leads to retargeting of the PRC2
and reduces cell differentiation.
Two key issues remain unclear. First, which factors lead
to a BRCA1-mutation DNAme pattern in the absence of a
BRCA1 mutation? It is likely that a combination of risk
factors or factors which we have not captured (for ex-
ample, early life events, transgenerational inheritance, and
so on) contribute to epigenetic modifications which are in
common to those associated with BRCA1 mutation. Sec-
ond, is the BRCA1-mutation DNAme signature in WBCs
functionally relevant or just simply an indicator of breast
cancer risk? The fact that the signature is indicative of
breast cancer mortality would support the view that subtleborative Trial of Ovarian Cancer Screening (UKCTOCS)
Methylation signature P value
Positive (SD) Negative (SD)
20.51 (16.74) 18.67 (10.09) 0.59
17.36 (8.32) 19.24 (8.11) 0.22
0.98 (0.58) 0.99 (0.55) 0.95
0.84 (0.43) 1.02 (0.59) 0.05
126.7 (156.59) 97.22 (58.10) 0.31
112.7 (91.86) 97.55 (92.41) 0.38
3.35 (1.66) 3.96 (2.00) 0.19
3.4 (2.10) 3.13 (1.41) 0.41
0.30 (0.17) 0.35 (0.20) 0.3
0.28 (0.17) 0.31 (0.19) 0.42
0.12 (0.08) 0.14 (0.10) 0.35
0.11 (0.07) 0.13 (0.09) 0.17
57.54 (37.71) 49.79 (19.86) 0.24
61.26 (26.46) 54.49 (24.36) 0.16
0.63 (2.13) 0.28 (0.21) 0.34
0.27 (0.17) 0.28 (0.16) 0.84
109.6 (57.54) 92.52 (56.75) 0.23
115.8 (65.49) 107.1 (57.92) 0.45
89.67 (87.33) 81.23 (56.48) 0.64
69.54 (62.56) 75.29 (61.84) 0.61
87.06 (122.37) 64.01 (75.85) 0.35
56.74 (62.83) 60.95 (72.14) 0.73
2.5 (0.95) 2.4 (0.91) 0.78
2.28 (1.11) 2.45 (0.96) 0.37
ores are the product of the methylation profile with the regression coefficients
lues were excluded from the analysis.
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http://genomemedicine.com/content/6/6/47epigenetic mis-programming of immune cells may lead to
general immune defects which in turn supports the devel-
opment and proliferation of cancers. However, all these
suggestions are highly speculative and need validation in
further independent cohorts using well-defined subsets of
blood cells or epithelial cells.
There are limitations to this study. First, we analysed
whole blood DNA or serum DNA representing whole
blood DNA and not a specific subset of peripheral blood
cells. Second, although we found some good preliminary
evidence that DNAme profiles in buccal cells are better
at predicting future breast cancer risk (data not shown),
we did not analyse buccal cells from BRCA1 mutation
carriers, nor did we have access to independent prospect-
ive buccal cell data. Third, we used the 27 k array, instead
of the 450 k array, to generate the BRCA1-mutation
DNAme signature.
In summary, our data highlight DNAme analysis as a
promising tool to predict future breast cancer develop-
ment. Future epigenome-wide studies should focus on
using epithelial cells like buccal - or epithelial cells from
the uterine cervix which are hormone sensitive and more
likely to capture an ‘epigenetic record’ of breast cancer
risk factors. Such studies are more likely to provide the
level of specificity and sensitivity which is required for a
clinically useful risk prediction tool.Conclusions
In summary, our DNAme signature derived from blood
cells from BRCA1 carriers is able to predict breast cancer
risk and death years in advance of diagnosis albeit with a
modest AUC. Our data further support the notion that
DNAme modification at stem-cell differentiation genes,
even in unrelated tissues, is an early event associated with
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